Navigation Links
Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
Date:4/27/2012

GREENWOOD VILLAGE, Colo., April 27, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion™, Optina™ and Zertane™), licensing distribution of these drugs and developing additional new drugs, today announced that it received notice of allowance of a patent from the US office of patents and trademarks for its DME drug Optina™. Ampio also received a notice of allowance of a similar patent from the Canadian Intellectual Property Office. These initial patents cover the North American territories and multiple additional patents for using Optina™ for the treatment of macular edema and diabetic retinopathy are pending worldwide.

According to Michael Macaluso, Ampio's CEO, "Optina™ is an ultra-low oral (capsule), not commercially available, dose of danazol for the treatment of DME. To our knowledge, no other oral drug to treat this condition exists and there is currently no drug approved by the FDA for this condition. The allowance of these patents in North America is an important step in the development and commercialization of this novel drug as they include multiple claims for the beneficial effects of ultra-low dose Optina™ on vascular hyperpermeability encountered in DME and other vascular leakage syndromes. These patents have an unusually long patent life that expires in 2030. In contrast, most drugs at this stage of development (just before a pivotal trial) have exhausted a large portion of their patent life. These patent claims provide especially strong protection because of the unexpected finding of efficacy only at the very low doses. Ampio is currently in discussions with potential partners to co-develop Optina™ for DME."

Dr. David Bar-Or, Chief Scientific Officer for Ampio, explained, "The mode of action of Optin
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ampio Strengthens Patent Protection for Lead Drug Ampion™
2. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
3. Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
4. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
5. Ampio Pharmaceuticals Schedules 2012 Outlook Webcast
6. Executive Changes at Ampio
7. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
8. Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
9. Ampio Responds to Recent Publications by Anonymous Short Sellers
10. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
11. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... (NYSE: EW ), the global leader in the ... net income for the quarter ended June 30, 2015 of ... income on a non-GAAP basis was $124.4 million, or ... share in the prior year period. In the year ... share, which included a $750 million payment to Edwards ...
(Date:7/28/2015)... 28, 2015   Regulus Therapeutics Inc . ( ... and development of innovative medicines targeting microRNAs, today announced ... the quarter ended June 30, 2015 on Tuesday, August ... Regulus will host a conference call and ... Eastern Daylight Time to discuss its second quarter 2015 ...
(Date:7/28/2015)... LOUIS, July 28, 2015  Express Scripts Holding Company ... income attributable to Express Scripts stockholders of $600.1 million, ... share, as detailed in Table 4, were $1.44 for ... is clear many companies across healthcare are validating the ... and Chief Executive Officer. "But, what matters most is ...
Breaking Medicine Technology:Edwards Lifesciences Reports Second Quarter Results 2Edwards Lifesciences Reports Second Quarter Results 3Edwards Lifesciences Reports Second Quarter Results 4Edwards Lifesciences Reports Second Quarter Results 5Edwards Lifesciences Reports Second Quarter Results 6Edwards Lifesciences Reports Second Quarter Results 7Edwards Lifesciences Reports Second Quarter Results 8Edwards Lifesciences Reports Second Quarter Results 9Edwards Lifesciences Reports Second Quarter Results 10Edwards Lifesciences Reports Second Quarter Results 11Edwards Lifesciences Reports Second Quarter Results 12Edwards Lifesciences Reports Second Quarter Results 13Edwards Lifesciences Reports Second Quarter Results 14Edwards Lifesciences Reports Second Quarter Results 15Edwards Lifesciences Reports Second Quarter Results 16Edwards Lifesciences Reports Second Quarter Results 17Edwards Lifesciences Reports Second Quarter Results 18Edwards Lifesciences Reports Second Quarter Results 19Edwards Lifesciences Reports Second Quarter Results 20Edwards Lifesciences Reports Second Quarter Results 21Edwards Lifesciences Reports Second Quarter Results 22Edwards Lifesciences Reports Second Quarter Results 23Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 2Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 4Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 5Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 6Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 7Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 8Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 9Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 10Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 11Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 12
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... gateways, and embedded building blocks for edge devices that enable the Internet of ... 4th generation Intel® Core™ i7/i5 processor to provide exceptional computing power and multitasking ...
(Date:7/28/2015)... ... July 28, 2015 , ... opaJUMP! ... measure and produce health outcomes associated with its training methods. This company is ... small group pre-post study, conducted in early 2015, training yielded an average 80% ...
(Date:7/28/2015)... ... ... Master flutist and solo artist Gary Stroutsos shares his deep resume of ... of serene, restorative instrumental music. Tracks carefully curated by White Swan producer Dubgoddess ... more -- to help the listener deeply breathe in a healing inner light for ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Egg freezing ... the procedure to help ensure future fertility. As Dr. Michael Kettel explained ... freezing is an option that wasn’t available for previous generations who had to make ...
(Date:7/28/2015)... ... ... to Kxan on June 24th a previously FDA approved blood pressure medication ... isradipine has garnered national attention and is making drug and alcohol rehabilitation medical physicians ... The study was conducted by the University of Texas. Human trials may be set ...
Breaking Medicine News(10 mins):Health News:ADLINK Launches High Performance, Fully-Sealed Medical-Grade Panel PC 2Health News:ADLINK Launches High Performance, Fully-Sealed Medical-Grade Panel PC 3Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 2Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 3Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 4Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 5Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 6Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 7Health News:Flute Meditations for Yoga & Massage: Calming Spa Music for Relaxation & Sleep by Gary Stroutsos 2Health News:Flute Meditations for Yoga & Massage: Calming Spa Music for Relaxation & Sleep by Gary Stroutsos 3Health News:Flute Meditations for Yoga & Massage: Calming Spa Music for Relaxation & Sleep by Gary Stroutsos 4Health News:Dr. Michael Kettel of San Diego Fertilty Center Interviewed by the San Diego Union-Tribune on Egg Freezing 2Health News:Dr. Michael Kettel of San Diego Fertilty Center Interviewed by the San Diego Union-Tribune on Egg Freezing 3Health News:Blood Pressure Medication May be the Key to Treating Addiction 2Health News:Blood Pressure Medication May be the Key to Treating Addiction 3
... Pain and Heat cannot coexist, because heat is capable of ... the use of DNA technology//, scientists were able to understand ... the heat is on, it has a pain relieving effect. ... par with a pain killer, because pain receptors are turned ...
... undergoing multiple tests to diagnose and investigate cardiovascular ... seemed to be promoted //by advanced imaging modalities. ... has recommended that an inter-disciplinary collaboration of various ... diagnosis could ensure effective diagnosis of heart diseases ...
... Medical Research (MIMR) have developed a new machine, named ... constantly. ,Although it was the first ... continuously, the fluctuating BP and brain oxygen levels of ... Monash Institute of Medical Research (MIMR) are carrying out ...
... University of Bristol have recommended that knee cartilage injuries ... any signs of osteoarthritis progression. ,'The ... only about 12 months and this is the first ... ,The study, 'Maturation of tissue engineered cartilage implanted ...
... whose parents were diagnosed with HIV was driven to ... ,Santosh Baniya succumbed to his burn injuries ... week. ,The boy’s parents, both vegetable sellers, ... have suggested that Santosh Baniya feared surviving his parents ...
... to a research conducted by Stephanie Chiuve it was found ... ailments//. ,U.S. researchers stated that patients suffering from ... lifestyle. ,It was discussed that middle aged men ... a proper diet and change their drinking and smoking habits. ...
Cached Medicine News:Health News:Collaborative use of Imaging Techniques proved effective in Cardiovascular Diagnosis – ESC Recommend 2Health News:Collaborative use of Imaging Techniques proved effective in Cardiovascular Diagnosis – ESC Recommend 3Health News:Preterm Babies Benefited from a New NI Spectroscopy 2Health News:Engineered Tissue Implants benefited Knee Injured patients 2
Gamma Glutamyl Transferase reagent is used for the quantitative determination of Gamma -GT in human serum....
For the quantitative kinetic determination of amylase activity, using manual or automated procedures, in human serum and urine....
For quantitative determination of amylase in human serum....
g-GT Liquid Reagent (Kinetic Method). Wavelength: 405 nm. Linear range: 0-200 U/mL. Prepare Working Reagent in the ratio of 5 parts R1 to 1 part of R2, (i.e., 50 mL R1 and 10 mL R2)....
Medicine Products: